{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,29]],"date-time":"2026-10-29T16:42:05Z","timestamp":1793292125007,"version":"4.5.0"},"reference-count":50,"publisher":"Society of Nuclear Medicine","issue":"12","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["J Nucl Med"],"accepted":{"date-parts":[[2025,8,26]]},"published-print":{"date-parts":[[2025,12]]},"DOI":"10.2967\/jnumed.125.270465","type":"journal-article","created":{"date-parts":[[2025,10,3]],"date-time":"2025-10-03T19:25:22Z","timestamp":1759519522000},"page":"1852-1858","source":"Crossref","is-referenced-by-count":7,"title":["Current Developments in Combining External-Beam Radiotherapy and\n                    <sup>177<\/sup>\n                    Lu-Labeled PSMA Ligands for Prostate Cancer Treatment"],"prefix":"10.2967","volume":"66","author":[{"given":"Frederik R.","family":"Teunissen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniela E.","family":"Oprea-Lager","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Steffie M.B.","family":"Peters","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert Jan","family":"Smeenk","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sandra","family":"Heskamp","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Johan","family":"Bussink","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1602","published-online":{"date-parts":[[2025,10,3]]},"reference":[{"key":"2026030506250588000_66.12.1852.1","doi-asserted-by":"crossref","first-page":"650","DOI":"10.1016\/j.annonc.2020.02.009","article-title":"European cancer mortality predictions for the year 2020 with a focus on prostate cancer","volume":"31","author":"Carioli","year":"2020","journal-title":"Ann Oncol."},{"key":"2026030506250588000_66.12.1852.2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(21)00233-6"},{"key":"2026030506250588000_66.12.1852.3","doi-asserted-by":"crossref","first-page":"1169","DOI":"10.3390\/cancers14051169","article-title":"Targeting PSMA revolutionizes the role of nuclear medicine in diagnosis and treatment of prostate cancer","volume":"14","author":"Luining","year":"2022","journal-title":"Cancers (Basel)."},{"key":"2026030506250588000_66.12.1852.4","doi-asserted-by":"crossref","first-page":"268","DOI":"10.1186\/s12885-023-10725-5","article-title":"Tolerability of concurrent external beam radiotherapy and [177Lu]Lu-PSMA-617 for node-positive prostate cancer in treatment naive patients, phase I study (PROQURE-I trial)","volume":"23","author":"van der Sar","year":"2023","journal-title":"BMC Cancer."},{"key":"2026030506250588000_66.12.1852.5","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1111\/bju.15988","article-title":"LUNAR: a randomized phase 2 study of 177lutetium-PSMA neoadjuvant to ablative radiotherapy for oligorecurrent prostate cancer (clinical trial protocol)","volume":"132","author":"Ma","year":"2023","journal-title":"BJU Int."},{"key":"2026030506250588000_66.12.1852.6","first-page":"P1178","article-title":"External beam therapy with theranostic radioligand therapy for oligometastatic prostate cancer (ProstACT TARGET)trial in progress [abstract]","volume":"64(suppl 1)","author":"Hawkins","year":"2023","journal-title":"J Nucl Med."},{"key":"2026030506250588000_66.12.1852.7","doi-asserted-by":"publisher","DOI":"10.2967\/jnumed.123.265763"},{"key":"2026030506250588000_66.12.1852.8","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1016\/j.eururo.2024.03.027","article-title":"EAU-EANM-ESTRO-ESUR-ISUP-SIOG guidelines on prostate cancer2024 update. Part I: screening, diagnosis, and local treatment with curative intent","volume":"86","author":"Cornford","year":"2024","journal-title":"Eur Urol."},{"key":"2026030506250588000_66.12.1852.9","doi-asserted-by":"publisher","DOI":"10.1016\/j.eururo.2024.04.010"},{"key":"2026030506250588000_66.12.1852.10","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.20.02873"},{"key":"2026030506250588000_66.12.1852.11","doi-asserted-by":"crossref","first-page":"5836","DOI":"10.1038\/s41598-021-85028-5","article-title":"The impact of the co-registration technique and analysis methodology in comparison studies between advanced imaging modalities and whole-mount-histology reference in primary prostate cancer","volume":"11","author":"Zamboglou","year":"2021","journal-title":"Sci Rep."},{"key":"2026030506250588000_66.12.1852.12","doi-asserted-by":"crossref","first-page":"110883","DOI":"10.1016\/j.radonc.2025.110883","article-title":"Safety and quality of life of PSMA-PET- and MRI-based focal dose escalated radiotherapy for intermediate- and high-risk prostate cancer: primary endpoint analysis of the bi-centric phase II HypoFocal trial (ARO2020-01)","volume":"208","author":"Spohn","year":"2025","journal-title":"Radiother Oncol."},{"key":"2026030506250588000_66.12.1852.13","doi-asserted-by":"crossref","first-page":"5795","DOI":"10.3390\/cancers13225795","article-title":"PSMA-PET\/MRI-based focal dose escalation in patients with primary prostate cancer treated with stereotactic body radiation therapy (HypoFocal-SBRT): study protocol of a randomized, multicentric phase III trial","volume":"13","author":"Zamboglou","year":"2021","journal-title":"Cancers (Basel)."},{"key":"2026030506250588000_66.12.1852.14","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1016\/j.euo.2019.07.010","article-title":"Oligometastatic prostate cancer: results of a Dutch multidisciplinary consensus meeting","volume":"3","author":"Aluwini","year":"2020","journal-title":"Eur Urol Oncol."},{"key":"2026030506250588000_66.12.1852.15","doi-asserted-by":"crossref","first-page":"650","DOI":"10.1001\/jamaoncol.2020.0147","article-title":"Outcomes of observation vs stereotactic ablative radiation for oligometastatic prostate cancer: the ORIOLE phase 2 randomized clinical trial","volume":"6","author":"Phillips","year":"2020","journal-title":"JAMA. Oncol."},{"key":"2026030506250588000_66.12.1852.16","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2017.75.4853"},{"key":"2026030506250588000_66.12.1852.17","doi-asserted-by":"crossref","first-page":"300","DOI":"10.1016\/S1470-2045(24)00730-7","article-title":"ADT with SBRT versus SBRT alone for hormone-sensitive oligorecurrent prostate cancer (RADIOSA): a randomised, open-label, phase 2 clinical trial","volume":"26","author":"Marvaso","year":"2025","journal-title":"Lancet Oncol."},{"key":"2026030506250588000_66.12.1852.18","doi-asserted-by":"crossref","first-page":"695","DOI":"10.1016\/S1470-2045(25)00197-4","article-title":"Salvage metastasis-directed therapy versus elective nodal radiotherapy for oligorecurrent nodal prostate cancer metastases (PEACE V-STORM): a phase 2, open-label, randomised controlled trial","volume":"26","author":"Ost","year":"2025","journal-title":"Lancet Oncol."},{"key":"2026030506250588000_66.12.1852.19","doi-asserted-by":"crossref","first-page":"695","DOI":"10.1016\/S1470-2045(25)00197-4","article-title":"Salvage metastasis-directed therapy versus elective nodal radiotherapy for oligorecurrent nodal prostate cancer metastases (PEACE V-STORM): a phase 2, open-label, randomised controlled trial","volume":"26","author":"Vis","year":"2025","journal-title":"Lancet Oncol"},{"key":"2026030506250588000_66.12.1852.20","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(18)32486-3"},{"key":"2026030506250588000_66.12.1852.21","doi-asserted-by":"publisher","DOI":"10.1016\/j.radonc.2022.05.024"},{"key":"2026030506250588000_66.12.1852.22","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2107322"},{"key":"2026030506250588000_66.12.1852.23","doi-asserted-by":"crossref","first-page":"3328","DOI":"10.1007\/s00259-022-05864-z","article-title":"EANM-EAU consensus on PSMA PET\/CT in respect to radioligand therapy ([177Lu]Lu-PSMA)","volume":"49","author":"Fanti","year":"2022","journal-title":"Eur J Nucl Med Mol Imaging."},{"key":"2026030506250588000_66.12.1852.24","doi-asserted-by":"crossref","first-page":"17588359231157632","DOI":"10.1177\/17588359231157632","article-title":"Status of PSMA-targeted radioligand therapy in prostate cancer: current data and future trials","volume":"15","author":"Jang","year":"2023","journal-title":"Ther Adv Med Oncol."},{"key":"2026030506250588000_66.12.1852.25","doi-asserted-by":"crossref","first-page":"768","DOI":"10.1186\/s13063-021-05733-4","article-title":"Update to a randomized controlled trial of lutetium-177-PSMA in oligo-metastatic hormone-sensitive prostate cancer: the BULLSEYE trial","volume":"22","author":"Prive","year":"2021","journal-title":"Trials."},{"key":"2026030506250588000_66.12.1852.26","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1016\/j.eururo.2023.08.026","article-title":"Administering [177Lu]Lu-PSMA-617 prior to radical prostatectomy in men with high-risk localised prostate cancer (LuTectomy): a single-centre, single-arm, phase 1\/2 study","volume":"85","author":"Eapen","year":"2024","journal-title":"Eur Urol."},{"key":"2026030506250588000_66.12.1852.27","doi-asserted-by":"publisher","DOI":"10.2967\/jnumed.121.262713"},{"key":"2026030506250588000_66.12.1852.28","doi-asserted-by":"crossref","first-page":"108971","DOI":"10.1016\/j.nucmedbio.2024.108971","article-title":"The potential of targeted radionuclide therapy to treat hypoxic tumor cells","volume":"140141","author":"Wenker","year":"2025","journal-title":"Nucl Med Biol."},{"key":"2026030506250588000_66.12.1852.29","doi-asserted-by":"publisher","DOI":"10.1016\/j.radonc.2012.10.006"},{"key":"2026030506250588000_66.12.1852.30","doi-asserted-by":"crossref","first-page":"3085","DOI":"10.1200\/JCO.21.00586","article-title":"Radiation dose escalation for early prostate cancer: reigniting the FLAME?","volume":"39","author":"Vogelius","year":"2021","journal-title":"J Clin Oncol."},{"key":"2026030506250588000_66.12.1852.31","doi-asserted-by":"crossref","first-page":"1413","DOI":"10.1056\/NEJMoa2403365","article-title":"Phase 3 trial of stereotactic body radiotherapy in localized prostate cancer","volume":"391","author":"van As","year":"2024","journal-title":"N Engl J Med."},{"key":"2026030506250588000_66.12.1852.32","doi-asserted-by":"crossref","first-page":"735","DOI":"10.1016\/j.clon.2021.09.004","article-title":"Combining external beam radiation and radionuclide therapies: rationale, radiobiology, results and roadblocks","volume":"33","author":"Abbott","year":"2021","journal-title":"Clin Oncol (R Coll Radiol)."},{"key":"2026030506250588000_66.12.1852.33","doi-asserted-by":"crossref","first-page":"2560","DOI":"10.7150\/thno.93249","article-title":"Exploring the role of combined external beam radiotherapy and targeted radioligand therapy with [177Lu]Lu-PSMA-617 for prostate cancer: from bench to bedside","volume":"14","author":"Arbuznikova","year":"2024","journal-title":"Theranostics."},{"key":"2026030506250588000_66.12.1852.34","doi-asserted-by":"crossref","first-page":"450","DOI":"10.3390\/pharmaceutics11090450","article-title":"Combination of proton therapy and radionuclide therapy in mice: preclinical pilot study at the Paul Scherrer Institute","volume":"11","author":"Mller","year":"2019","journal-title":"Pharmaceutics."},{"key":"2026030506250588000_66.12.1852.35","doi-asserted-by":"crossref","first-page":"704","DOI":"10.1097\/RLU.0000000000001763","article-title":"Combination of 177Lu-PSMA-617 and external radiotherapy for the treatment of cerebral metastases in patients with castration-resistant metastatic prostate cancer","volume":"42","author":"Wei","year":"2017","journal-title":"Clin Nucl Med."},{"key":"2026030506250588000_66.12.1852.36","doi-asserted-by":"crossref","unstructured":"Mohammadi S Pompa IR Haberman V . Combination metastasis-targeted external beam radiation therapy with 177Lu-PSMA-617 in patients with advanced castration-resistant prostate cancer. Pract Radiat Oncol. April 22, 2025 [Epub ahead of print].","DOI":"10.1016\/j.prro.2025.03.010"},{"key":"2026030506250588000_66.12.1852.37","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(21)00237-3"},{"key":"2026030506250588000_66.12.1852.38","doi-asserted-by":"crossref","first-page":"20150042","DOI":"10.1259\/bjr.20150042","article-title":"Improving external beam radiotherapy by combination with internal irradiation","volume":"88","author":"Dietrich","year":"2015","journal-title":"Br J Radiol."},{"key":"2026030506250588000_66.12.1852.39","first-page":"159","article-title":"Enhancement of monoclonal antibody uptake in human colon tumor xenografts following irradiation","volume":"50","author":"Kalofonos","year":"1990","journal-title":"Cancer Res."},{"key":"2026030506250588000_66.12.1852.40","doi-asserted-by":"crossref","first-page":"3104","DOI":"10.1158\/1078-0432.CCR-21-4531","article-title":"Prostate-specific membrane antigen expression and response to DNA damaging agents in prostate cancer","volume":"28","author":"Sheehan","year":"2022","journal-title":"Clin Cancer Res."},{"key":"2026030506250588000_66.12.1852.41","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijrobp.2009.09.040"},{"key":"2026030506250588000_66.12.1852.42","doi-asserted-by":"crossref","first-page":"556","DOI":"10.1002\/mp.14622","article-title":"Important pharmacokinetic parameters for individualization of 177Lu-PSMA therapy: a global sensitivity analysis for a physiologically-based pharmacokinetic model","volume":"48","author":"Hardiansyah","year":"2021","journal-title":"Med Phys."},{"key":"2026030506250588000_66.12.1852.43","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1053\/j.semnuclmed.2021.11.003","article-title":"Radiation dosimetry in 177Lu-PSMA-617 therapy","volume":"52","author":"Jackson","year":"2022","journal-title":"Semin Nucl Med."},{"key":"2026030506250588000_66.12.1852.44","doi-asserted-by":"crossref","first-page":"1778","DOI":"10.1007\/s00259-022-05727-7","article-title":"EANM dosimetry committee recommendations for dosimetry of 177Lu-labelled somatostatin-receptor- and PSMA-targeting ligands","volume":"49","author":"Sjogreen Gleisner","year":"2022","journal-title":"Eur J Nucl Med Mol Imaging."},{"key":"2026030506250588000_66.12.1852.45","doi-asserted-by":"crossref","first-page":"2064","DOI":"10.1007\/s00259-021-05661-0","article-title":"89Zr-labeled PSMA ligands for pharmacokinetic PET imaging and dosimetry of PSMA-617 and PSMA-I&T: a preclinical evaluation and first in man","volume":"49","author":"Prive","year":"2022","journal-title":"Eur J Nucl Med Mol Imaging."},{"key":"2026030506250588000_66.12.1852.46","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1186\/s13550-023-00952-z","article-title":"Optimization of the radiation dosimetry protocol in lutetium-177-PSMA therapy: toward clinical implementation","volume":"13","author":"Peters","year":"2023","journal-title":"EJNMMI Res."},{"key":"2026030506250588000_66.12.1852.47","doi-asserted-by":"publisher","DOI":"10.2967\/jnumed.122.264594"},{"key":"2026030506250588000_66.12.1852.48","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1016\/S1470-2045(23)00638-1","article-title":"Actinium-225-PSMA radioligand therapy of metastatic castration-resistant prostate cancer (WARMTH Act): a multicentre, retrospective study","volume":"25","author":"Sathekge","year":"2024","journal-title":"Lancet Oncol."},{"key":"2026030506250588000_66.12.1852.49","doi-asserted-by":"publisher","DOI":"10.1016\/j.radonc.2022.10.005"},{"key":"2026030506250588000_66.12.1852.50","doi-asserted-by":"publisher","DOI":"10.1016\/j.eururo.2025.01.010"}],"container-title":["Journal of Nuclear Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.2967\/jnumed.125.270465","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,28]],"date-time":"2026-07-28T20:19:14Z","timestamp":1785269954000},"score":1,"resource":{"primary":{"URL":"http:\/\/jnm.snmjournals.org\/lookup\/doi\/10.2967\/jnumed.125.270465"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10,3]]},"references-count":50,"journal-issue":{"issue":"12","published-online":{"date-parts":[[2025,12,3]]},"published-print":{"date-parts":[[2025,12]]}},"alternative-id":["10.2967\/jnumed.125.270465"],"URL":"https:\/\/doi.org\/10.2967\/jnumed.125.270465","relation":{},"ISSN":["0161-5505","2159-662X"],"issn-type":[{"value":"0161-5505","type":"print"},{"value":"2159-662X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,10,3]]}}}